© 2020 MJH Life Sciences and Contagion Live. All rights reserved.
© 2020 MJH Life Sciences™ and Contagion Live. All rights reserved.
April 15, 2020
Community-acquired infections—including those associated with outpatient settings—are still problematic, authors say.
March 31, 2020
After the MODIFY trial, investigators wanted to explore how bezlotoxumab treated patients in the real world.
March 18, 2020
Results from England’s first licensed FMT stool bank are now available.
March 05, 2020
An electronic alert that aids in diagnostic stewardship may be helpful in reducing inappropriate testing for C diff, according to a new study.
February 27, 2020
Using enteral vancomycin for C diff prophylaxis may be the key to reducing morbidity and improving outcomes in pediatric and young adult recipients of HSCT.
February 19, 2020
System hospitals are proactive in reducing incidence of C diff infections and CLABSIs, according to study in JAMA Network Open.
The new C diff strain may turn out to be particularly severe and requires sufficient monitoring.
February 07, 2020
Rebiotix has announced that it has completed enrollment of a phase 3 clinical trial for RBX2660.
Treatment with bezlotoxumab resulted in a statistically significant reduction of recurrent C diff in cancer patients, according to a new study.
January 23, 2020
Infection with C diff can increase hospital length of stay between 3 and 21 days, new research says.